Tissue plasminogen activator and neuropathy open the blood-nerve barrier with upregulation of microRNA-155-5p in male rats.
Animals
Blood-Nerve Barrier
/ drug effects
Chronic Disease
Constriction, Pathologic
/ complications
Hyperalgesia
/ etiology
Male
MicroRNAs
/ genetics
Neuralgia
/ etiology
Peripheral Nervous System Diseases
/ drug therapy
Rats, Wistar
Recombinant Proteins
/ pharmacology
Tight Junction Proteins
/ drug effects
Tissue Plasminogen Activator
/ genetics
Up-Regulation
/ drug effects
(4–6): Chronic constriction injury
Adherens junction
Blood nerve barrier
Neuropathic pain
Tight junction
microRNA
Journal
Biochimica et biophysica acta. Molecular basis of disease
ISSN: 1879-260X
Titre abrégé: Biochim Biophys Acta Mol Basis Dis
Pays: Netherlands
ID NLM: 101731730
Informations de publication
Date de publication:
01 06 2019
01 06 2019
Historique:
received:
05
07
2018
revised:
30
11
2018
accepted:
04
01
2019
pubmed:
10
1
2019
medline:
6
2
2020
entrez:
10
1
2019
Statut:
ppublish
Résumé
The blood-nerve barrier (BNB) consisting of the perineurium and endoneurial vessels is sealed by tight junction proteins. BNB alterations are a crucial factor in the pathogenesis of peripheral neuropathies. However, barrier opening, e.g. by tissue plasminogen activator (tPA), can also facilitate topical application of analgesics. Here, we examined tPA both in the pathophysiology of neuropathy-induced BNB opening or via exogenous application and its effect on the cytoplasmatic tight junction protein anchoring protein, zona occludens-1 (ZO-1), the adherens molecule JAM-C and microRNA(miR)-155-5p. Specifically, we investigated whether tPA alone and barrier opening lead to pain behavioral changes, i.e. hyperalgesia, or whether these effects require further factors. Male Wistar rats underwent chronic constriction injury (CCI) or were treated by a single perisciatic application of recombinant (r)tPA. CCI elicited mechanical allodynia, tPA mRNA upregulation, macrophage invasion, BNB leakage for large molecule tracers, downregulation of ZO-1 and JAM-C mRNA/protein, and a loss of immunoreactivity of both in perineurium and endoneurial cells. Similarly, after perisciatic rtPA injection, ZO-1 and JAM-C mRNA as well as cytosolic/membrane protein and ZO-1 immunoreactivity were downregulated, and the BNB was opened. Neither mechanical hypersensitivity nor macrophage infiltration was observed after rtPA in contrast to CCI. Mechanistically, miR-155-5p, which is known to destabilize barriers and tight junction proteins like claudin-1 and ZO-1, was increased in CCI and to lesser extent after rtPA application. In summary, tPA transiently opens the BNB possibly via miR-155-5p. However, tPA does not provoke allodynia in the absence of a neuropathic stimulus like a ligation or inflammation.
Identifiants
pubmed: 30625382
pii: S0925-4439(19)30008-0
doi: 10.1016/j.bbadis.2019.01.008
pii:
doi:
Substances chimiques
MIRN155 microRNA, rat
0
MicroRNAs
0
Recombinant Proteins
0
Tight Junction Proteins
0
Tissue Plasminogen Activator
EC 3.4.21.68
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1160-1169Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.